Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-10-16

UNITED THERAPEUTICS Corp (UTHR)

CEO Martine Rothblatt was paid $18,038,972 in fiscal year 2025, ↓ down 21.6% from fiscal year 2024, the 54th percentile of its disclosed peer group (SEC filing 0001082554-26-000009 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$18,038,972 ↓
Martine Rothblatt total, FY2025
54th
CEO pay percentile vs peers
76:1
CEO-to-median pay ratio
97.05%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Martine Rothblatt (Chairperson and Chief Executive Officer), FY2025 total compensation $18,038,972 (base salary $1,545,005) [exec_comp, SEC accession 0001082554-26-000009, filed 2026-04-29]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

UTHR's next annual pay disclosure, estimated April 29, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Martine Rothblatt$1,545,005$0$6,067,990$6,075,804$4,281,875$55,898$12,400$18,038,972
Chairperson and Chief Executive Officer
Michael Benkowitz1,442,30803,121,5583,124,1343,315,0003,328,73553,92014,385,655
President and Chief Operating Officer
James Edgemond955,76901,950,9741,953,1331,616,0631,849,38123,0478,348,367
Chief Financial Officer and Treasurer
Paul Mahon964,23101,517,7661,519,2261,500,590029,5005,531,313
Executive Vice President and General Counsel

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Martine Rothblatt$18,038,972$23,009,609$16,958,057↓ −4,970,637
Michael Benkowitz14,385,65513,893,3899,806,551↑ +492,266
James Edgemond8,348,3679,164,5496,054,484↓ −816,182
Paul Mahon5,531,3136,963,3085,153,601↓ −1,431,995

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read UNITED THERAPEUTICS Corp's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper UTHR reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the UNITED THERAPEUTICS Corp Peer Teardown Report

$18,038,972 Martine Rothblatt total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of October 16, 2026 · Source: 0001082554-26-000009 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for UTHR

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
UTHRon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order UTHR

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against UTHR
25 companies name UTHR as a compensation peer

Each company listed discloses UTHR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named UTHR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the UNITED THERAPEUTICS Corp Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Christopher CauseyIndependent Director$508,034
Christopher PatuskyLead Independent Director$541,312
Jan MalcolmIndependent Director$470,265
Judy OlianIndependent Director$476,397
Linda MaxwellIndependent Director$489,556
Louis SullivanIndependent Director$499,127
Nilda MesaIndependent Director$493,743
Ray KurzweilIndependent Director$463,743
Raymond DwekIndependent Director$484,784
Richard GiltnerIndependent Director$501,397
Tommy ThompsonIndependent Director$483,034
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Martine RothblattDirector2026-10-01D560$573$320,803CommonForm 4 ↗
Martine RothblattDirector2026-10-01D320572182,888CommonForm 4 ↗
Martine RothblattDirector2026-10-01D534571304,673CommonForm 4 ↗
Martine RothblattDirector2026-10-01D16056390,130CommonForm 4 ↗
Martine RothblattDirector2026-10-01D8056244,934CommonForm 4 ↗
Martine RothblattDirector2026-10-01D9,50000Derivative, Class A CommonForm 4 ↗
Martine RothblattDirector2026-10-01D360585210,478CommonForm 4 ↗
Martine RothblattDirector2026-10-01D400583233,313CommonForm 4 ↗
Martine RothblattDirector2026-10-01D702581408,012CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D16057391,704CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D838571478,411CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D400566226,562CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D1,480563833,374CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01A8,3001461,212,049CommonForm 4 ↗
Martine RothblattDirector2026-10-01D320579185,286CommonForm 4 ↗
Martine RothblattDirector2026-10-01D930578537,477CommonForm 4 ↗
Martine RothblattDirector2026-10-01D9456853,383CommonForm 4 ↗
Martine RothblattDirector2026-10-01A9,5001181,118,720CommonForm 4 ↗
Martine RothblattDirector2026-10-01D306570174,314CommonForm 4 ↗
Martine RothblattDirector2026-10-01D520582302,765CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D720568408,788CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D780562438,259CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D1,480560829,083CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D880558491,308CommonForm 4 ↗
Martine RothblattDirector2026-10-01D774577446,525CommonForm 4 ↗
Martine RothblattDirector2026-10-01D12056067,206CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D8,30000Derivative, Class A CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D823572470,961CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-01D739569420,600CommonForm 4 ↗
Martine RothblattDirector2026-10-02D4057422,969CommonForm 4 ↗
Martine RothblattDirector2026-10-02D12057168,484CommonForm 4 ↗
Martine RothblattDirector2026-10-02D240570136,775CommonForm 4 ↗
Martine RothblattDirector2026-10-02D8056745,326CommonForm 4 ↗
Martine RothblattDirector2026-10-02D8056445,110CommonForm 4 ↗
Martine RothblattDirector2026-10-02D12056167,279CommonForm 4 ↗
Martine RothblattDirector2026-10-02D12055967,032CommonForm 4 ↗
Martine RothblattDirector2026-10-02D240557133,784CommonForm 4 ↗
Martine RothblattDirector2026-10-02D8055644,448CommonForm 4 ↗
Martine RothblattDirector2026-10-02D8055444,344CommonForm 4 ↗
Martine RothblattDirector2026-10-02D725552400,067CommonForm 4 ↗
Martine RothblattDirector2026-10-02D432551238,027CommonForm 4 ↗
Martine RothblattDirector2026-10-02D757550416,040CommonForm 4 ↗
Martine RothblattDirector2026-10-02D1,171548641,699CommonForm 4 ↗
Martine RothblattDirector2026-10-02D309547168,945CommonForm 4 ↗
Martine RothblattDirector2026-10-02D1,280545697,471CommonForm 4 ↗
Martine RothblattDirector2026-10-02D408543221,492CommonForm 4 ↗
Martine RothblattDirector2026-10-02D700542379,443CommonForm 4 ↗
Martine RothblattDirector2026-10-02A9,5001181,118,720CommonForm 4 ↗
Martine RothblattDirector2026-10-02D1,032544561,589CommonForm 4 ↗
Martine RothblattDirector2026-10-02D16055388,457CommonForm 4 ↗
Martine RothblattDirector2026-10-02D8057245,795CommonForm 4 ↗
Martine RothblattDirector2026-10-02D4056222,494CommonForm 4 ↗
Martine RothblattDirector2026-10-02D1,206549661,943CommonForm 4 ↗
Martine RothblattDirector2026-10-02D9,50000Derivative, Class A CommonForm 4 ↗
Martine RothblattDirector2026-10-05D9,50000Derivative, Class A CommonForm 4 ↗
Martine RothblattDirector2026-10-05D360547196,788CommonForm 4 ↗
Martine RothblattDirector2026-10-05D1,260545686,187CommonForm 4 ↗
Martine RothblattDirector2026-10-05D783544425,593CommonForm 4 ↗
Martine RothblattDirector2026-10-05D918543498,067CommonForm 4 ↗
Martine RothblattDirector2026-10-05D1,239542671,120CommonForm 4 ↗
Martine RothblattDirector2026-10-05D1,028540555,633CommonForm 4 ↗
Martine RothblattDirector2026-10-05D931540502,279CommonForm 4 ↗
Martine RothblattDirector2026-10-05D655539352,795CommonForm 4 ↗
Martine RothblattDirector2026-10-05D905537486,373CommonForm 4 ↗
Martine RothblattDirector2026-10-05D501536268,665CommonForm 4 ↗
Martine RothblattDirector2026-10-05D920546502,037CommonForm 4 ↗
Martine RothblattDirector2026-10-05A9,5001181,118,720CommonForm 4 ↗
Martine RothblattDirector2026-10-06D9,50000Derivative, Class A CommonForm 4 ↗
Martine RothblattDirector2026-10-06D8054543,640CommonForm 4 ↗
Martine RothblattDirector2026-10-06D842545458,681CommonForm 4 ↗
Martine RothblattDirector2026-10-06D558544303,548CommonForm 4 ↗
Martine RothblattDirector2026-10-06D380542205,791CommonForm 4 ↗
Martine RothblattDirector2026-10-06D2,0545411,110,553CommonForm 4 ↗
Martine RothblattDirector2026-10-06D1,606540866,718CommonForm 4 ↗
Martine RothblattDirector2026-10-06D1,088539586,006CommonForm 4 ↗
Martine RothblattDirector2026-10-06D13353871,498CommonForm 4 ↗
Martine RothblattDirector2026-10-06D734536393,210CommonForm 4 ↗
Martine RothblattDirector2026-10-06D16753489,228CommonForm 4 ↗
Martine RothblattDirector2026-10-06D360529190,339CommonForm 4 ↗
Martine RothblattDirector2026-10-06D280528147,813CommonForm 4 ↗
Martine RothblattDirector2026-10-06D323536173,209CommonForm 4 ↗
Martine RothblattDirector2026-10-06D215533114,626CommonForm 4 ↗
Martine RothblattDirector2026-10-06D320532170,220CommonForm 4 ↗
Martine RothblattDirector2026-10-06D240530127,232CommonForm 4 ↗
Martine RothblattDirector2026-10-06D12054265,099CommonForm 4 ↗
Martine RothblattDirector2026-10-06A9,5001181,118,720CommonForm 4 ↗
Martine RothblattDirector2026-10-07D9,50000Derivative, Class A CommonForm 4 ↗
Martine RothblattDirector2026-10-07D400556222,594CommonForm 4 ↗
Martine RothblattDirector2026-10-07D485555268,939CommonForm 4 ↗
Martine RothblattDirector2026-10-07D185554102,435CommonForm 4 ↗
Martine RothblattDirector2026-10-07D440552243,010CommonForm 4 ↗
Martine RothblattDirector2026-10-07D486551267,832CommonForm 4 ↗
Martine RothblattDirector2026-10-07D387548212,145CommonForm 4 ↗
Martine RothblattDirector2026-10-07D629547344,028CommonForm 4 ↗
Martine RothblattDirector2026-10-07D2,0985451,143,035CommonForm 4 ↗
Martine RothblattDirector2026-10-07D744544404,557CommonForm 4 ↗
Martine RothblattDirector2026-10-07D17654395,521CommonForm 4 ↗
Martine RothblattDirector2026-10-07D874550480,819CommonForm 4 ↗
Martine RothblattDirector2026-10-07D493546269,104CommonForm 4 ↗
Martine RothblattDirector2026-10-07D1,173549644,130CommonForm 4 ↗
Martine RothblattDirector2026-10-07D930556516,869CommonForm 4 ↗
Martine RothblattDirector2026-10-07A9,5001181,118,720CommonForm 4 ↗
Martine RothblattDirector2026-10-08D9,50000Derivative, Class A CommonForm 4 ↗
Martine RothblattDirector2026-10-08D424541229,175CommonForm 4 ↗
Martine RothblattDirector2026-10-08D1,091540588,682CommonForm 4 ↗
Martine RothblattDirector2026-10-08D1,016538546,134CommonForm 4 ↗
Martine RothblattDirector2026-10-08D824537442,165CommonForm 4 ↗
Martine RothblattDirector2026-10-08D480535257,020CommonForm 4 ↗
Martine RothblattDirector2026-10-08D920534491,539CommonForm 4 ↗
Martine RothblattDirector2026-10-08D800533426,689CommonForm 4 ↗
Martine RothblattDirector2026-10-08D600532319,244CommonForm 4 ↗
Martine RothblattDirector2026-10-08D1,061531563,468CommonForm 4 ↗
Martine RothblattDirector2026-10-08D199530105,497CommonForm 4 ↗
Martine RothblattDirector2026-10-08D200529105,725CommonForm 4 ↗
Martine RothblattDirector2026-10-08D273528144,028CommonForm 4 ↗
Martine RothblattDirector2026-10-08D767527403,951CommonForm 4 ↗
Martine RothblattDirector2026-10-08D200525105,099CommonForm 4 ↗
Martine RothblattDirector2026-10-08A9,5001181,118,720CommonForm 4 ↗
Martine RothblattDirector2026-10-08D4054121,649CommonForm 4 ↗
Martine RothblattDirector2026-10-08D605539325,853CommonForm 4 ↗
Martine RothblattDirector2026-10-09D9,50000Derivative, Class A CommonForm 4 ↗
Martine RothblattDirector2026-10-09D423551232,954CommonForm 4 ↗
Martine RothblattDirector2026-10-09D1,478550812,796CommonForm 4 ↗
Martine RothblattDirector2026-10-09D878548481,155CommonForm 4 ↗
Martine RothblattDirector2026-10-09D240547131,184CommonForm 4 ↗
Martine RothblattDirector2026-10-09D400546218,360CommonForm 4 ↗
Martine RothblattDirector2026-10-09D400545217,818CommonForm 4 ↗
Martine RothblattDirector2026-10-09D240543130,371CommonForm 4 ↗
Martine RothblattDirector2026-10-09D4054221,660CommonForm 4 ↗
Martine RothblattDirector2026-10-09D200539107,846CommonForm 4 ↗
Martine RothblattDirector2026-10-09D360537193,337CommonForm 4 ↗
Martine RothblattDirector2026-10-09D400536214,436CommonForm 4 ↗
Martine RothblattDirector2026-10-09D320534170,816CommonForm 4 ↗
Martine RothblattDirector2026-10-09D12053263,830CommonForm 4 ↗
Martine RothblattDirector2026-10-09A9,5001181,118,720CommonForm 4 ↗
Martine RothblattDirector2026-10-09D2,6415491,449,736CommonForm 4 ↗
Martine RothblattDirector2026-10-09D320541173,037CommonForm 4 ↗
Martine RothblattDirector2026-10-09D400538215,330CommonForm 4 ↗
Martine RothblattDirector2026-10-09D640535342,270CommonForm 4 ↗
Martine RothblattDirector2026-10-12D13555474,852CommonForm 4 ↗
Martine RothblattDirector2026-10-12D558553308,535CommonForm 4 ↗
Martine RothblattDirector2026-10-12D1,8575521,024,920CommonForm 4 ↗
Martine RothblattDirector2026-10-12D2,6285511,448,297CommonForm 4 ↗
Martine RothblattDirector2026-10-12D2,5655501,410,825CommonForm 4 ↗
Martine RothblattDirector2026-10-12D1,329549729,639CommonForm 4 ↗
Martine RothblattDirector2026-10-12D428548234,599CommonForm 4 ↗
Martine RothblattDirector2026-10-12A9,5001181,118,720CommonForm 4 ↗
Martine RothblattDirector2026-10-12D9,50000Derivative, Class A CommonForm 4 ↗
Martine RothblattDirector2026-10-13D9,50000Derivative, Class A CommonForm 4 ↗
Martine RothblattDirector2026-10-13D8055144,119CommonForm 4 ↗
Martine RothblattDirector2026-10-13D16055188,095CommonForm 4 ↗
Martine RothblattDirector2026-10-13D502549275,833CommonForm 4 ↗
Martine RothblattDirector2026-10-13D698548382,844CommonForm 4 ↗
Martine RothblattDirector2026-10-13D630547344,908CommonForm 4 ↗
Martine RothblattDirector2026-10-13D1,452546793,459CommonForm 4 ↗
Martine RothblattDirector2026-10-13D1,507546822,102CommonForm 4 ↗
Martine RothblattDirector2026-10-13D2,3405431,271,750CommonForm 4 ↗
Martine RothblattDirector2026-10-13D639543346,822CommonForm 4 ↗
Martine RothblattDirector2026-10-13A9,5001181,118,720CommonForm 4 ↗
Martine RothblattDirector2026-10-13D1,492545812,483CommonForm 4 ↗
Martine RothblattDirector2026-10-14D9,50000Derivative, Class A CommonForm 4 ↗
Martine RothblattDirector2026-10-14D4054621,840CommonForm 4 ↗
Martine RothblattDirector2026-10-14D480545261,830CommonForm 4 ↗
Martine RothblattDirector2026-10-14D480544261,289CommonForm 4 ↗
Martine RothblattDirector2026-10-14D400543217,262CommonForm 4 ↗
Martine RothblattDirector2026-10-14D883542478,644CommonForm 4 ↗
Martine RothblattDirector2026-10-14D1,9305411,044,509CommonForm 4 ↗
Martine RothblattDirector2026-10-14D2,0025401,081,544CommonForm 4 ↗
Martine RothblattDirector2026-10-14D525539283,023CommonForm 4 ↗
Martine RothblattDirector2026-10-14D1,127538606,326CommonForm 4 ↗
Martine RothblattDirector2026-10-14D633537340,039CommonForm 4 ↗
Martine RothblattDirector2026-10-14D400536214,356CommonForm 4 ↗
Martine RothblattDirector2026-10-14D240535128,312CommonForm 4 ↗
Martine RothblattDirector2026-10-14D4053221,299CommonForm 4 ↗
Martine RothblattDirector2026-10-14D12053163,742CommonForm 4 ↗
Martine RothblattDirector2026-10-14D16053084,814CommonForm 4 ↗
Martine RothblattDirector2026-10-14D4052621,043CommonForm 4 ↗
Martine RothblattDirector2026-10-14A9,5001181,118,720CommonForm 4 ↗
Martine RothblattDirector2026-10-15D12055266,180CommonForm 4 ↗
Martine RothblattDirector2026-10-15D200551110,143CommonForm 4 ↗
Martine RothblattDirector2026-10-15D1,009550554,704CommonForm 4 ↗
Martine RothblattDirector2026-10-15D2,0395491,119,183CommonForm 4 ↗
Martine RothblattDirector2026-10-15D2,1665481,186,593CommonForm 4 ↗
Martine RothblattDirector2026-10-15D601547328,713CommonForm 4 ↗
Martine RothblattDirector2026-10-15D825546450,347CommonForm 4 ↗
Martine RothblattDirector2026-10-15D269545146,539CommonForm 4 ↗
Martine RothblattDirector2026-10-15D371543201,599CommonForm 4 ↗
Martine RothblattDirector2026-10-15D456543247,462CommonForm 4 ↗
Martine RothblattDirector2026-10-15D1,163542629,864CommonForm 4 ↗
Martine RothblattDirector2026-10-15D281540151,874CommonForm 4 ↗
Martine RothblattDirector2026-10-15A9,5001181,118,720CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-15D8,30000Derivative, Class A CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-15D719547392,977CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-15D2,6155461,426,972CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-15D791545430,975CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-15D1,9835441,077,871CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-15D1,9245421,043,753CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-15D268542145,160CommonForm 4 ↗
Paul MahonEVP & GENERAL COUNSEL2026-10-15A8,3001461,212,049CommonForm 4 ↗
Martine RothblattDirector2026-10-15D9,50000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Michael BenkowitzPSU2025-03-1414,22028,440—85,320$3,124,134
Martine RothblattPSU2025-03-1427,65555,310—165,9306,075,804
Paul MahonPSU2025-03-141,2352,470—7,410758,883
Michael BenkowitzPSU2025-03-142,5405,080—15,2401,560,779
James EdgemondPSU2025-03-148,89017,780—53,3401,953,133
Paul MahonPSU2025-03-146,91513,830—41,4901,519,226
James EdgemondPSU2025-03-141,5883,175—9,525975,487
Martine RothblattPSU2025-03-144,9389,875—29,6253,033,995
Paul MahonPSU2025-03-141,2352,470—7,410758,883
James EdgemondPSU2025-03-141,5883,175—9,525975,487
Martine RothblattPSU2025-03-144,9389,875—29,6253,033,995
Michael BenkowitzPSU2025-03-142,5405,080—15,2401,560,779
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Michael Benkowitz$0$6,245,692$0100.0%
Martine Rothblatt012,143,7940100.0%
Paul Mahon03,036,9920100.0%
James Edgemond03,904,1070100.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
James EdgemondRSU10,380—$5,057,655
Martine RothblattRSU48,315—23,541,484
Martine RothblattRSU37,080—18,067,230
Michael BenkowitzRSU15,592—7,597,202
Martine RothblattRSU32,499—15,835,138
Martine RothblattRSU29,625—14,434,781
Michael BenkowitzRSU24,840—12,103,290
Michael BenkowitzRSU17,790—8,668,178
James EdgemondRSU15,525—7,564,556
Michael BenkowitzRSU15,240—7,425,690
Paul MahonRSU12,075—5,883,544
James EdgemondRSU9,525—4,641,056
James EdgemondOption58,170217.5—
James EdgemondRSU9,098—4,433,001
Paul MahonRSU8,895—4,334,089
Paul MahonRSU7,796—3,798,601
Paul MahonRSU7,410—3,610,523
Martine RothblattOption207,720217.5—
Michael BenkowitzOption99,720217.5—
Paul MahonOption49,860217.5—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is designed to retain and motivate our executive team, while achieving four critical objectives: pay-for-performance (with at-risk pay representing approximately 91.1% of overall Chief Executive Officer pay and approximately 83.6% of our other NEOs’ pay); incentivize alignment with shareholder interests based on delivering operating performance and stock appreciation; balancing incentives over the short-term and long-term; and market competitiveness.

CEO STI target (% of salary)125%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-2635,152,0591,048,50518,31397.05%Passed
20252025-06-2638,413,7761,763,71229,22595.54%Passed
20242024-06-2635,662,9951,974,53049,32794.63%Passed
20232023-06-2638,688,6511,188,503220,61196.49%Passed
20222022-06-2738,935,752690,79181,70598.05%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-2697.05%a
20252025-06-2695.54%b
20242024-06-2694.63%c

a. Approved under the standard stated in the filing — “Abstentions have the same effect as an "against" vote.”.

b. Approved under the standard stated in the filing — “Abstentions have the same effect as an "against" vote.”.

c. Approved under the standard stated in the filing — “Abstentions have the same effect as a "against" vote.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)76 : 1
CEO total compensation$18,038,972
Median employee compensation$237,406
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Christopher PatuskyIndependent · Lead Independent Director · Compensation (Chair) · Nominating/Governance$137,569$199,167$204,576$0$0$541,312
Christopher CauseyIndependent · Nominating/Governance (Chair) · Audit100,0000408,03400508,034
Richard GiltnerIndependent · Audit (Chair) · Nominating/Governance100,000401,397000501,397
Louis SullivanIndependent · Compensation83,478199,167204,576011,906499,127
Nilda MesaIndependent · Compensation · Nominating/Governance90,000199,167204,57600493,743
Linda MaxwellIndependent · Compensation · Nominating/Governance81,5220408,03400489,556
Raymond DwekIndependent · Compensation · Not standing for re-election75,0000408,03401,750484,784
Tommy ThompsonIndependent · Audit75,0000408,03400483,034
Judy OlianIndependent · Audit75,000401,397000476,397
Jan MalcolmIndependent · Audit66,522199,167204,57600470,265
Ray KurzweilIndependent60,000199,167204,57600463,743
Martine RothblattEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$60,000
Annual equity retainer$400,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)—
Stock ownership guideline$5,000
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$944,091
Equity awards (grant-date value)$1,798,629
All other compensation$13,656
Total cost of the board$2,756,376

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies UNITED THERAPEUTICS Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including UNITED THERAPEUTICS Corp.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exelixis2025Michael Morrissey$1,306,040$30,539,552$0$1,382,591$33,239,183
2Incyte2025William Meury647,26027,509,6572,573,9981,300,00032,085,952
3Gilead Sciences2025Daniel O'Day1,795,19215,238,4024,500,0604,848,12028,437,198
4Amgen2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
5Biogen2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
6PTC Therapeutics2025Matthew Klein958,50016,593,8004,399,7601,294,00023,266,326
7Halozyme Therapeutics2025Helen Torley1,000,00019,350,1451,650,0141,147,50023,166,223
8BioMarin Pharmaceuticals2025Alexander Hardy1,130,76916,833,6291,909,3101,644,50021,927,563
9Vertex Pharmaceuticals2025Reshma Kewalramani1,600,00015,002,27004,118,64021,144,261
10Moderna2025Stéphane Bancel1,677,7396,897,4556,897,4254,302,36019,932,217
11Jazz Pharmaceuticals2025Renee Gala1,003,26916,138,43301,980,00019,151,558
12UNITED THERAPEUTICS Corp2025Martine Rothblatt1,545,0056,067,9906,075,8044,281,87518,038,972
13Viatris2025Scott Smith1,448,65410,150,01302,973,66015,273,331
14Alnylam Pharmaceuticals2025Yvonne Greenstreet1,404,2005,512,5004,363,3803,562,50014,867,600
15Neurocrine Biosciences2025Kyle Gano920,0005,750,0235,750,006013,448,935
16Ionis Pharmaceuticals2025Brett Monia1,051,7768,444,8381,438,105013,350,777
17Pacira BioSciences2025Frank Lee935,3089,215,5000738,81011,636,917
18Illumina2025Jacob Thaysen1,000,0008,763,12201,155,00011,018,895
19Novavax2025John Jacobs792,9173,545,4353,763,292640,3318,856,015
20Amphastar Pharmaceuticals2025Jack Yongfeng Zhang950,9113,301,9813,302,024361,0008,309,350
21ACADIA Pharmaceuticals2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
22Alkermes2025Richard Pops1,250,76905,020,8121,626,0007,915,081
23Sarepta Therapeutics2025Douglas Ingram1,171,4256,000,0050649,0007,840,666
24Regeneron Pharmaceuticals2025Leonard Schleifer1,979,922003,682,6557,280,549
25Myriad Genetics2025Samraat Raha856,9013,989,7290814,6605,686,740

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
UNITED THERAPEUTICS Corp221%PSO 50 · PSU 50NoAon
ACADIA Pharmaceuticals110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Alkermes130%PRSU 53 · RSU 24 · Option 23Yes — Relative Total Shareholder Return (TSR)Alpine Rewards LLC
Alnylam Pharmaceuticals200%PSU 50 · RSU 25 · Option 25NoPay Governance
Amgen136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
Amphastar Pharmaceuticalsnot disclosedOptions 50 · RSU 50not disclosedWillis Towers Watson (WTW)
Biogen127%PSU 60 · RSU 40YesPay Governance
BioMarin Pharmaceuticals130%PSU 66 · RSU 21 · Options 13Yes — Relative TSRAon Human Capital Solutions
Exelixis105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Gilead Sciences180%PSU 50 · Options 25 · RSU 25Yes — Relative TSRFW Cook
Halozyme Therapeutics127.5%PSU 50 · RSU 35 · Option 15NoF.W. Cook & Co., Inc.
Illumina1155%not disclosedYes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology IndexAon (Aon's Human Capital Practice, a division of Aon, plc)
Incyte138.6%Performance Shares 60 · RSU 40Yes — relative total shareholder return (TSR)Aon
Ionis Pharmaceuticalsnot disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Jazz Pharmaceuticals150%PSU 50 · RSU 50Yes — Relative TSRAon
Moderna170%PSU 50 · Options 50NoPay Governance LLC
Myriad Genetics89%RSU 50 · PSU 50YesMercer, LLC
Neurocrine Biosciences105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
Novavax95%Options 50 · RSU 50not disclosedPearl Meyer
Pacira BioSciences90%RSU 80 · PSU 20NoAon
PTC Therapeuticsnot disclosedOption 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFrederic W. Cook & Co., Inc.
Regeneron Pharmaceuticals155%Options 60 · RSU 40not disclosedPay Governance LLC
Sarepta Therapeutics100%PSU 50 · Option 25 · RSU 25NoFW Cook
Vertex Pharmaceuticalsnot disclosedPSU 55 · RSU 45Nonot disclosed
Viatris136.72%PSU 65 · RSU 35NoMeridian Compensation Partners, LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at UNITED THERAPEUTICS Corp in fiscal 2025?
As disclosed, Martine Rothblatt (Chairperson and Chief Executive Officer) was the highest-paid executive at UNITED THERAPEUTICS Corp in fiscal 2025, with total compensation of $18,038,972.
How does UNITED THERAPEUTICS Corp's chief executive pay compare to its disclosed peer group?
As disclosed, Martine Rothblatt's total compensation ranked at the 54th percentile of UNITED THERAPEUTICS Corp's disclosed peer group.
What is UNITED THERAPEUTICS Corp's CEO-to-median employee pay ratio?
As disclosed, UNITED THERAPEUTICS Corp's CEO-to-median employee pay ratio was 76:1.
How did shareholders vote on UNITED THERAPEUTICS Corp's executive compensation?
As disclosed, 97.05% of shareholders supported UNITED THERAPEUTICS Corp's executive compensation in the latest say-on-pay vote.
How much does UNITED THERAPEUTICS Corp spend in total on board compensation for fiscal 2025?
As disclosed, UNITED THERAPEUTICS Corp reported total board compensation of $2,756,376 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Martine RothblattDEF 14A2026-04-290001082554-26-000009Section “Summary Compensation Table” · page 50. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736
2Section 01, Michael BenkowitzDEF 14A2026-04-290001082554-26-000009Section “Summary Compensation Table” · page 50. As printed: 14,385,655. Filing ↗machine: r8 · c9 · span 2031448–2031458
3Section 01, James EdgemondDEF 14A2026-04-290001082554-26-000009Section “Summary Compensation Table” · page 50. As printed: 8,348,367. Filing ↗machine: r5 · c9 · span 2012964–2012973
4Section 01, Paul MahonDEF 14A2026-04-290001082554-26-000009Section “Summary Compensation Table” · page 50. As printed: 5,531,313. Filing ↗machine: r11 · c9 · span 2049879–2049888
5Section 03, Michael Benkowitz PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2186148–2186157
6Section 03, Martine Rothblatt PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2146795–2146804
7Section 03, Paul Mahon PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2210262–2210269
8Section 03, Michael Benkowitz PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2190876–2190885
9Section 03, James Edgemond PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2166461–2166470
10Section 03, Paul Mahon PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2205536–2205545
11Section 03, James Edgemond PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2171187–2171194
12Section 03, Martine Rothblatt PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2151517–2151526
13Section 03, Paul Mahon PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2214980–2214987
14Section 03, James Edgemond PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2175905–2175912
15Section 03, Martine Rothblatt PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2156233–2156242
16Section 03, Michael Benkowitz PSUDEF 14A1900-01-010001082554-26-000009Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2195598–2195607
17Section 07, pay ratioDEF 14A2026-04-290001082554-26-000009Section “CEO Pay Ratio”. As printed: 76 : 1. Filing ↗
18Section 08, Christopher PatuskyDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 541,312. Filing ↗machine: span 1241075–1241667
19Section 08, Christopher CauseyDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 508,034. Filing ↗machine: span 1204302–1204893
20Section 08, Richard GiltnerDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 501,397. Filing ↗machine: span 1213675–1214268
21Section 08, Louis SullivanDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 499,127. Filing ↗machine: span 1245560–1246155
22Section 08, Nilda MesaDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 493,743. Filing ↗machine: span 1231931–1232525
23Section 08, Linda MaxwellDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 489,556. Filing ↗machine: span 1227368–1227963
24Section 08, Raymond DwekDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 484,784. Filing ↗machine: span 1209098–1209692
25Section 08, Tommy ThompsonDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 483,034. Filing ↗machine: span 1250124–1250718
26Section 08, Judy OlianDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 476,397. Filing ↗machine: span 1236513–1237108
27Section 08, Jan MalcolmDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 470,265. Filing ↗machine: span 1222786–1223377
28Section 08, Ray KurzweilDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 463,743. Filing ↗machine: span 1218238–1218832
29Section 08, Martine RothblattDEF 14A2026-04-290001082554-26-000009Section “Director Compensation”. As printed: 0. Filing ↗
30Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Martine Rothblatt 2026-10-01Form 42026-10-020001106578-26-000155Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Paul Mahon 2026-10-01Form 42026-10-010001231589-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Martine Rothblatt 2026-10-02Form 42026-10-050001106578-26-000156Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Martine Rothblatt 2026-10-05Form 42026-10-060001106578-26-000157Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Martine Rothblatt 2026-10-06Form 42026-10-070001106578-26-000158Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Martine Rothblatt 2026-10-07Form 42026-10-080001106578-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Martine Rothblatt 2026-10-08Form 42026-10-090001106578-26-000160Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Martine Rothblatt 2026-10-09Form 42026-10-130001106578-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Martine Rothblatt 2026-10-12Form 42026-10-130001106578-26-000162Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Martine Rothblatt 2026-10-12Form 42026-10-130001106578-26-000162Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Martine Rothblatt 2026-10-12Form 42026-10-130001106578-26-000162Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Martine Rothblatt 2026-10-12Form 42026-10-130001106578-26-000162Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Martine Rothblatt 2026-10-12Form 42026-10-130001106578-26-000162Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Martine Rothblatt 2026-10-12Form 42026-10-130001106578-26-000162Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Martine Rothblatt 2026-10-12Form 42026-10-130001106578-26-000162Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Martine Rothblatt 2026-10-12Form 42026-10-130001106578-26-000162Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Martine Rothblatt 2026-10-12Form 42026-10-130001106578-26-000162Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, Martine Rothblatt 2026-10-13Form 42026-10-140001106578-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
200Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
201Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
202Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
203Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
204Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
205Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
206Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
207Section 02, Martine Rothblatt 2026-10-14Form 42026-10-150001106578-26-000164Insider equity transaction reported since the proxy statement. Filing ↗
208Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
209Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
210Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
211Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
212Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
213Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
214Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
215Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
216Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
217Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
218Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
219Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
220Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
221Section 02, Paul Mahon 2026-10-15Form 42026-10-160001231589-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
222Section 02, Paul Mahon 2026-10-15Form 42026-10-160001231589-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
223Section 02, Paul Mahon 2026-10-15Form 42026-10-160001231589-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
224Section 02, Paul Mahon 2026-10-15Form 42026-10-160001231589-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
225Section 02, Paul Mahon 2026-10-15Form 42026-10-160001231589-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
226Section 02, Paul Mahon 2026-10-15Form 42026-10-160001231589-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
227Section 02, Paul Mahon 2026-10-15Form 42026-10-160001231589-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
228Section 02, Paul Mahon 2026-10-15Form 42026-10-160001231589-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
229Section 02, Martine Rothblatt 2026-10-15Form 42026-10-160001106578-26-000165Insider equity transaction reported since the proxy statement. Filing ↗
230Section 06, 2026 voteForm 8-K2026-06-290001104659-26-078865Item 5.07 · say-on-pay result. As reported: 97.05% (votes for as printed: 35,152,059). Filing ↗
231Section 06, 2025 voteForm 8-K2025-06-270001104659-25-063287Item 5.07 · say-on-pay result. As reported: 95.54% (votes for as printed: 38,413,776). Filing ↗
232Section 06, 2024 voteForm 8-K2024-06-270001104659-24-075375Item 5.07 · say-on-pay result. As reported: 94.63% (votes for as printed: 35,662,995). Filing ↗
233Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
234Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
235Section 09b board cost (computed)Computed——Cash 944,091 + equity 1,798,629 + all other 13,656 = 2,756,376, summed across the director compensation table rows.machine: formula: Σ = 2,756,376
236Exelixis, Section 10b CEO totalDEF 14A2026-04-150000939767-26-000046CEO total compensation as printed in Exelixis's own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526
237Incyte, Section 10b CEO totalDEF 14A2026-04-280000879169-26-000031CEO total compensation as printed in Incyte's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
238Gilead Sciences, Section 10b CEO totalDEF 14A2026-03-200001308179-26-000106CEO total compensation as printed in Gilead Sciences's own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592
239Amgen, Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen's own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
240Biogen, Section 10b CEO totalDEF 14A2026-04-280001193125-26-187303CEO total compensation as printed in Biogen's own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
241PTC Therapeutics, Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗
242Halozyme Therapeutics, Section 10b CEO totalDEF 14A2026-03-230001159036-26-000041CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292
243BioMarin Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-210001628280-26-026290CEO total compensation as printed in BioMarin Pharmaceuticals's own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915
244Vertex Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-020000875320-26-000153CEO total compensation as printed in Vertex Pharmaceuticals's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809
245Moderna, Section 10b CEO totalDEF 14A2026-03-160001308179-26-000081CEO total compensation as printed in Moderna's own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898
246Jazz Pharmaceuticals, Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
247UNITED THERAPEUTICS Corp (subject), Section 10b CEO totalDEF 14A2026-04-290001082554-26-000009CEO total compensation as printed in UNITED THERAPEUTICS Corp's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736
248Viatris, Section 10b CEO totalDEF 14A2026-04-020001140361-26-013002CEO total compensation as printed in Viatris's own proxy. As printed: 15,273,331. Filing ↗machine: r2 · c28 · span 1344008–1344018
249Alnylam Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-060001628280-26-023923CEO total compensation as printed in Alnylam Pharmaceuticals's own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701
250Neurocrine Biosciences, Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
251Ionis Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗
252Pacira BioSciences, Section 10b CEO totalDEF 14A2026-04-280001104659-26-050353CEO total compensation as printed in Pacira BioSciences's own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168
253Illumina, Section 10b CEO totalDEF 14A2026-04-090001193125-26-149669CEO total compensation as printed in Illumina's own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536
254Novavax, Section 10b CEO totalDEF 14A2026-04-270001628280-26-027328CEO total compensation as printed in Novavax's own proxy. As printed: 8,856,015. Filing ↗machine: r2 · c24 · span 944385–944394
255Amphastar Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-130001297184-26-000023CEO total compensation as printed in Amphastar Pharmaceuticals's own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932
256ACADIA Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in ACADIA Pharmaceuticals's own proxy. As printed: 8,256,518. Filing ↗
257Alkermes, Section 10b CEO totalDEF 14A2026-04-060001193125-26-143977CEO total compensation as printed in Alkermes's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267
258Sarepta Therapeutics, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177247CEO total compensation as printed in Sarepta Therapeutics's own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404
259Regeneron Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-240001308179-26-000340CEO total compensation as printed in Regeneron Pharmaceuticals's own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989
260Myriad Genetics, Section 10b CEO totalDEF 14A2026-04-140000899923-26-000031CEO total compensation as printed in Myriad Genetics's own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792986–792996
261Section 10a, BioMarin Pharmaceuticals reciprocityDEF 14A—0001628280-26-026290BioMarin Pharmaceuticals names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
262Section 10a, Jazz Pharmaceuticals reciprocityDEF 14A—0001232524-26-000029Jazz Pharmaceuticals names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
263Section 10a, Exelixis reciprocityDEF 14A—0000939767-26-000046Exelixis names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
264Section 10a, Alnylam Pharmaceuticals reciprocityDEF 14A—0001628280-26-023923Alnylam Pharmaceuticals names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
265Section 10a, Gilead Sciences reciprocityDEF 14A—0001308179-26-000106Gilead Sciences's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗
266Section 10a, Vertex Pharmaceuticals reciprocityDEF 14A—0000875320-26-000153Vertex Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗
267Section 10a, Amgen reciprocityDEF 14A—0001193125-26-145588Amgen's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗
268Section 10a, Amphastar Pharmaceuticals reciprocityDEF 14A—0001297184-26-000023Amphastar Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗
269Section 10a, Pacira BioSciences reciprocityDEF 14A—0001104659-26-050353Pacira BioSciences's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗
270Section 10a, PTC Therapeutics reciprocityDEF 14A—0001104659-26-045528PTC Therapeutics's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗
271Section 10a, Novavax reciprocityDEF 14A—0001628280-26-027328Novavax's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗
272Section 10a, Sarepta Therapeutics reciprocityDEF 14A—0001193125-26-177247Sarepta Therapeutics names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
273Section 10a, ACADIA Pharmaceuticals reciprocityDEF 14A—0001193125-26-174163ACADIA Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗
274Section 10a, Halozyme Therapeutics reciprocityDEF 14A—0001159036-26-000041Halozyme Therapeutics names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
275Section 10a, Moderna reciprocityDEF 14A—0001308179-26-000081Moderna names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
276Section 10a, Regeneron Pharmaceuticals reciprocityDEF 14A—0001308179-26-000340Regeneron Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗
277Section 10a, Neurocrine Biosciences reciprocityDEF 14A—0000914475-26-000015Neurocrine Biosciences names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
278Section 10a, Viatris reciprocityDEF 14A—0001140361-26-013002Viatris's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗
279Section 10a, Ionis Pharmaceuticals reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the UNITED THERAPEUTICS Corp Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
UTHR Peer Teardown Report